Literature DB >> 21056892

HIV-1 infects macrophages by exploiting an endocytic route dependent on dynamin, Rac1 and Pak1.

Gemma C Carter1, Laura Bernstone, Darshan Baskaran, William James.   

Abstract

Recent studies provide compelling evidence that HIV-1 entry in cell lines and lymphocytes proceeds by endocytosis, but these studies are still lacking in macrophages, an important natural target cell for HIV-1. Macrophages exhibit continual and extensive endocytic activity as part of their natural functions, so we investigated the uptake pathways involved in productive HIV-1 entry. We find that caveolae are not utilised by HIV-1, because the main structural proteins, caveolin-1 and 2 are absent from most human leukocytes. We then focused on macropinocytosis; we find that HIV-1 entry into macrophages is sensitive to inhibitors of Na(+)/H(+) exchange, actin rearrangement, dynamin, Rho family GTPases, and Pak1, but not to inhibitors of PI-3 kinase and myosin II. This leads us to conclude that HIV entry into macrophages proceeds by an endocytic pathway that is not classical macropinocytosis. Because of the limitations of a purely pharmacological study such as this, the final elucidation of this pathway awaits the development of reliable forward genetic approaches in authentic macrophages.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21056892     DOI: 10.1016/j.virol.2010.10.018

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  57 in total

1.  Viral infection: Moving through complex and dynamic cell-membrane structures.

Authors:  Jonathan Barroso-González; Laura García-Expósito; Julià Blanco; Agustín Valenzuela-Fernández; Isabel Puigdomènech; Laura de Armas-Rillo; José-David Machado
Journal:  Commun Integr Biol       Date:  2011-07-01

2.  High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.

Authors:  Mariana Marin; Yuhong Du; Charline Giroud; Jeong Hwa Kim; Min Qui; Haian Fu; Gregory B Melikyan
Journal:  Assay Drug Dev Technol       Date:  2015-04-14       Impact factor: 1.738

3.  Distinct requirements for HIV-cell fusion and HIV-mediated cell-cell fusion.

Authors:  Naoyuki Kondo; Mariana Marin; Jeong Hwa Kim; Tanay M Desai; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2015-01-14       Impact factor: 5.157

4.  Macropinocytosis-like HIV-1 internalization in macrophages is CCR5 dependent and leads to efficient but delayed degradation in endosomal compartments.

Authors:  Lise-Andrée Gobeil; Robert Lodge; Michel J Tremblay
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

5.  Productive entry of HIV-1 during cell-to-cell transmission via dynamin-dependent endocytosis.

Authors:  Richard D Sloan; Björn D Kuhl; Thibault Mesplède; Jan Münch; Daniel A Donahue; Mark A Wainberg
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

Review 6.  Novel anti-HIV therapeutics targeting chemokine receptors and actin regulatory pathways.

Authors:  Mark Spear; Jia Guo; Yuntao Wu
Journal:  Immunol Rev       Date:  2013-11       Impact factor: 12.988

7.  RNA-Associated Early-Stage Antiviral Factor Is a Major Component of Lv2 Restriction.

Authors:  Kelly M Marno; Eithne O'Sullivan; Christopher E Jones; Julieta Díaz-Delfín; Claire Pardieu; Richard D Sloan; Áine McKnight
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

8.  Caveolin-1 suppresses human immunodeficiency virus-1 replication by inhibiting acetylation of NF-κB.

Authors:  Glenn E Simmons; Harry E Taylor; James E K Hildreth
Journal:  Virology       Date:  2012-06-28       Impact factor: 3.616

Review 9.  HIV entry: a game of hide-and-fuse?

Authors:  Gregory B Melikyan
Journal:  Curr Opin Virol       Date:  2013-11-01       Impact factor: 7.090

Review 10.  Viral exploitation of actin: force-generation and scaffolding functions in viral infection.

Authors:  Mark Spear; Yuntao Wu
Journal:  Virol Sin       Date:  2014-06-06       Impact factor: 4.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.